Table 1 Therapies targeting NETs in wound healing.
From: The emerging roles of neutrophil extracellular traps in wound healing
Mechanism | Drug/Method | Administration | Wound healing outcome | Ref. |
|---|---|---|---|---|
PAD4 inhibitor | PAD4-/- in normoglycemic wound | No H3cit was detected; wounds were healed 80% on day 14 and 25% in WT controls | [7] | |
PAD4-/- in diabetic wound | Healed >35% faster, wound area reduced by 28% | [7] | ||
CI-amidine | 10 mg/kg i.v. | H3cit and wound aera decreased | [12] | |
Tripeptide (Thr-Asp-F-amidine) | Topically | Wound closure and re-epithelialization accelerated | [98] | |
DNase 1 | Pulmozyme | 10 mg/kg i.p. | Superior scar scores and wound closure time | [96] |
Dornase alfa | 10 μg i.v. 50 μg i.p. | Wound area reduced by >20% and re-epithelialization by 75% | [7] | |
Deoxyribonuclease I from bovine pancreas | Topically | Inflammatory response reduced; re-epithelialization and healing accelerated | [84] | |
ROS production and MAPK activation | Na2S | 50 μmol/kg i.p. | NETs reduced; NE activity decreased; wound healing accelerated | [105] |
NET formation | GnRH antagonist | Wound size reduced | [89] | |
LRG-1 ablation | Wound size reduced | [87] | ||
PKC β inhibitor | Metformin | Orally | NETs reduced | [91] |
Ruboxistaurin | Orally | Wound closure accelerated, nearly complete re-epithelialization by 14 days | [88] | |
NLRP3 inflammasome-NET axis | Recombinant mouse MFG-E8 | 500 ng/ml | NETs reduced, NETs-primed NLRP3 inflammasome was inhibited | [86] |
NET structure | Clarithromycin | 2 μg/ml for 210 min | LL-37 increased, fibroblasts activated, collagen increased | [64] |
